Metagenomi is pioneering the development of next-generation genetic medicines through its innovative metagenomics-powered genome editing toolbox. By leveraging the vast diversity of microbial life, the company extracts genetic material from natural environments, allowing for the discovery of novel genome editing tools that surpass current technologies. Their approach involves systematic expeditions to collect microbial samples, followed by DNA sequencing and genome reconstruction to build a comprehensive metagenomics database. This database is then interrogated using advanced artificial intelligence and machine learning algorithms to identify high-performing CRISPR nucleases and other effector enzymes, which are essential for precise and efficient gene editing.

The company's modular engineering strategy enables the combination of various genome editing components, such as programmable nucleases and base editing systems, to create tailored solutions for specific therapeutic targets. Metagenomi has successfully identified over 20,000 unique genome editing systems, which are continuously refined to enhance their targetability, specificity, and efficiency. This iterative and high-throughput discovery platform positions Metagenomi at the forefront of genetic medicine, aiming to address significant unmet clinical needs and establish new standards in therapeutic precision and efficacy.

United States

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

Metagenomi

Company Details